Cargando…
Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
The first-line therapy in advanced kidney cancer has changed in recent years due to the introduction of combinations of tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptors (VEGFR) and immune checkpoint inhibitors (ICIs). Although immune-related adverse events are well-k...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755843/ https://www.ncbi.nlm.nih.gov/pubmed/36530979 http://dx.doi.org/10.3389/fonc.2022.1048526 |
_version_ | 1784851509658255360 |
---|---|
author | Boutros, Andrea Vera, Lara Gatto, Federico Fornarini, Giuseppe Zanardi, Elisa |
author_facet | Boutros, Andrea Vera, Lara Gatto, Federico Fornarini, Giuseppe Zanardi, Elisa |
author_sort | Boutros, Andrea |
collection | PubMed |
description | The first-line therapy in advanced kidney cancer has changed in recent years due to the introduction of combinations of tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptors (VEGFR) and immune checkpoint inhibitors (ICIs). Although immune-related adverse events are well-known, in the case of combination treatments, the determination of which drug is related to an adverse event may be challenging. We reported two cases of patients who developed muscle enzyme elevation in association with hypothyroidism during therapy with pembrolizumab plus axitinib for metastatic kidney cancer. The myopathy rapidly resolved after hormone replacement therapy with levothyroxine. Hypothyroid myopathy is a scarcely known and underreported adverse event. This adverse event may be relevant in the differential diagnosis with immune-related myositis, which has an autoimmune pathogenesis and a potentially fatal course. |
format | Online Article Text |
id | pubmed-9755843 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97558432022-12-17 Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients Boutros, Andrea Vera, Lara Gatto, Federico Fornarini, Giuseppe Zanardi, Elisa Front Oncol Oncology The first-line therapy in advanced kidney cancer has changed in recent years due to the introduction of combinations of tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptors (VEGFR) and immune checkpoint inhibitors (ICIs). Although immune-related adverse events are well-known, in the case of combination treatments, the determination of which drug is related to an adverse event may be challenging. We reported two cases of patients who developed muscle enzyme elevation in association with hypothyroidism during therapy with pembrolizumab plus axitinib for metastatic kidney cancer. The myopathy rapidly resolved after hormone replacement therapy with levothyroxine. Hypothyroid myopathy is a scarcely known and underreported adverse event. This adverse event may be relevant in the differential diagnosis with immune-related myositis, which has an autoimmune pathogenesis and a potentially fatal course. Frontiers Media S.A. 2022-12-02 /pmc/articles/PMC9755843/ /pubmed/36530979 http://dx.doi.org/10.3389/fonc.2022.1048526 Text en Copyright © 2022 Boutros, Vera, Gatto, Fornarini and Zanardi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Boutros, Andrea Vera, Lara Gatto, Federico Fornarini, Giuseppe Zanardi, Elisa Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients |
title | Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients |
title_full | Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients |
title_fullStr | Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients |
title_full_unstemmed | Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients |
title_short | Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients |
title_sort | case report: pembrolizumab plus axitinib related hypothyroid myopathy in two kidney cancer patients |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755843/ https://www.ncbi.nlm.nih.gov/pubmed/36530979 http://dx.doi.org/10.3389/fonc.2022.1048526 |
work_keys_str_mv | AT boutrosandrea casereportpembrolizumabplusaxitinibrelatedhypothyroidmyopathyintwokidneycancerpatients AT veralara casereportpembrolizumabplusaxitinibrelatedhypothyroidmyopathyintwokidneycancerpatients AT gattofederico casereportpembrolizumabplusaxitinibrelatedhypothyroidmyopathyintwokidneycancerpatients AT fornarinigiuseppe casereportpembrolizumabplusaxitinibrelatedhypothyroidmyopathyintwokidneycancerpatients AT zanardielisa casereportpembrolizumabplusaxitinibrelatedhypothyroidmyopathyintwokidneycancerpatients |